West Pharmaceutical Services (NYSE:WST) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Saturday.
Several other equities analysts also recently issued reports on WST. Zacks Investment Research raised shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Goldman Sachs assumed coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 24th. They set a “neutral” rating and a $110.00 price target for the company. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. West Pharmaceutical Services currently has a consensus rating of “Hold” and a consensus target price of $108.17.
Shares of WST stock opened at $83.32 on Friday. West Pharmaceutical Services has a 12-month low of $77.97 and a 12-month high of $103.36. The stock has a market cap of $6,355.44, a P/E ratio of 29.97, a PEG ratio of 2.20 and a beta of 1.11. The company has a quick ratio of 1.89, a current ratio of 2.66 and a debt-to-equity ratio of 0.15.
West Pharmaceutical Services announced that its board has authorized a stock repurchase plan on Thursday, February 15th that authorizes the company to repurchase 800,000 shares. This repurchase authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Xact Kapitalforvaltning AB acquired a new stake in West Pharmaceutical Services in the 4th quarter valued at about $641,000. Envestnet Asset Management Inc. increased its position in West Pharmaceutical Services by 42.7% in the 4th quarter. Envestnet Asset Management Inc. now owns 49,678 shares of the medical instruments supplier’s stock valued at $4,902,000 after acquiring an additional 14,856 shares in the last quarter. William Blair Investment Management LLC increased its position in West Pharmaceutical Services by 43.2% in the 4th quarter. William Blair Investment Management LLC now owns 1,272,407 shares of the medical instruments supplier’s stock valued at $125,548,000 after acquiring an additional 383,646 shares in the last quarter. MetLife Investment Advisors LLC acquired a new stake in West Pharmaceutical Services in the 4th quarter valued at about $4,636,000. Finally, Jane Street Group LLC increased its position in West Pharmaceutical Services by 16.8% in the 4th quarter. Jane Street Group LLC now owns 6,307 shares of the medical instruments supplier’s stock valued at $622,000 after acquiring an additional 907 shares in the last quarter. Hedge funds and other institutional investors own 94.39% of the company’s stock.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.